Targeted Tumor Sequencing

Fillmore and his collaborators have utilized targeted tumor sequencing to identify molecular signatures that stratify patients with advanced prostate cancer into distinct clinical subgroups. This research demonstrates that hierarchical clustering of somatic mutations can reveal targetable genomic alterations, including novel mutations in PTEN and MSH6. Such findings suggest that precise molecular profiling is essential for guiding personalized therapeutic interventions in precision oncology.